IL-23 and IL-17 in ankylosing spondylitis

[1]  J. Weinberg.  Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial , 2010 .

[2]  J. Goodall,et al.  Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. , 2009, Arthritis and rheumatism.

[3]  C. Farrar,et al.  Association between the interleukin 23 receptor and ankylosing spondylitis is confirmed by a new UK case-control study and meta-analysis of published series. , 2009, Rheumatology.

[4]  Zhiming Lin,et al.  Expression of IL-23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis , 2009, Rheumatology International.

[5]  A. Gottlieb,et al.  Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial , 2009, The Lancet.

[6]  D. Wendling,et al.  Serum and synovial fluid levels of p40 IL12/23 in spondyloarthropathy patients , 2009, Clinical Rheumatology.

[7]  D. Wendling.  Interleukin 23: a key cytokine in chronic inflammatory disease. , 2008, Joint, bone, spine : revue du rhumatisme.

[8]  D. Speiser,et al.  Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. , 2008, Arthritis and rheumatism.

[9]  D. Wendling,et al.  Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. , 2007, Joint, bone, spine : revue du rhumatisme.